US2007041974A1PendingUtilityA1

Cytokine zalpha11 ligand antibodies

62
Assignee: ZYMOGENETICS INCPriority: Mar 9, 1999Filed: Oct 16, 2006Published: Feb 22, 2007
Est. expiryMar 9, 2019(expired)· nominal 20-yr term from priority
Inventors:Julia E. NovakScott R. PresnellCindy A. SprecherDonald C. FosterRichard D. HollyJane A. GrossJanet V. JohnstonAndrew J. NelsonStacey R. DillonAngela K. Hammond
A01K 2267/03A61P 35/02C07K 2319/00C07K 16/2866A61K 38/00C07K 2319/30A01K 2227/105C12N 15/8509C12N 15/62A61P 35/00C12N 2799/026A61P 37/02A61P 7/00C07K 14/001A61K 38/18C07K 14/715C07K 16/24C07K 14/5406C07K 2319/24C07K 14/52C07K 2319/21C07K 2317/73G01N 2333/52A01K 2217/05C07K 2319/55C07K 14/535C07K 14/54A01K 67/0275
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.

Claims

exact text as granted — not AI-modified
1 . An antibody which binds to a polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residue 1 to 162.  
     
     
         2 . An antibody which binds to a polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residue 32 to 162.  
     
     
         3 . An antibody which binds to a polypeptide comprising a sequence of at least 15 contiguous amino acid residues as shown in SEQ ID NO: 2.  
     
     
         4 . The antibody of  claim 3 , wherein the polypeptide sequence has at least 30 contiguous amino acid residues.  
     
     
         5 . The antibody of  claim 3 , wherein the polypeptide sequence has at least 100 contiguous amino acid residues.  
     
     
         6 . The antibody of  claim 1 , wherein the antibody is polyclonal.  
     
     
         7 . The antibody of  claim 1 , wherein the antibody is monoclonal.  
     
     
         8 . The antibody of  claim 1 , wherein the antibody is murine.  
     
     
         9 . The antibody of  claim 8 , wherein the antibody is humanized.  
     
     
         10 . The antibody of  claim 1 , wherein the antibody is neutralizing.  
     
     
         11 . An antibody fragment which binds to a polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residue 1 to 162.  
     
     
         12 . An antibody which binds to a peptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residues 114 to 119.  
     
     
         13 . The antibody of  claim 12 , wherein the antibody is monoclonal.  
     
     
         14 . The antibody of  claim 12 , wherein the antibody is murine.  
     
     
         15 . The antibody of  claim 12 , wherein the antibody is humanized.  
     
     
         16 . The antibody of  claim 12 , wherein the antibody is neutralizing.  
     
     
         17 . An antibody which binds to a peptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residues 101 to 105.  
     
     
         18 . The antibody of  claim 17 , wherein the antibody is monoclonal.  
     
     
         19 . The antibody of  claim 17 , wherein the antibody is murine.  
     
     
         20 . The antibody of  claim 17 , wherein the antibody is humanized.  
     
     
         21 . The antibody of  claim 17 , wherein the antibody is neutralizing.  
     
     
         22 . An antibody which binds to a peptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residues 126 to 131.  
     
     
         23 . The antibody of  claim 22 , wherein the antibody is monoclonal.  
     
     
         24 . The antibody of  claim 22 , wherein the antibody is murine.  
     
     
         25 . The antibody of  claim 22 , wherein the antibody is humanized.  
     
     
         26 . The antibody of  claim 22 , wherein the antibody is neutralizing.  
     
     
         27 . An antibody which binds to a peptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residues 113 to 118.  
     
     
         28 . The antibody of  claim 27 , wherein the antibody is monoclonal.  
     
     
         29 . The antibody of  claim 27 , wherein the antibody is murine.  
     
     
         30 . The antibody of  claim 27 , wherein the antibody is humanized.  
     
     
         31 . The antibody of  claim 27 , wherein the antibody is neutralizing.  
     
     
         32 . An antibody which binds to a peptide comprising a sequence of amino acid residues as shown in SEQ ID NO: 2 from residues 158 to 162.  
     
     
         33 . The antibody of  claim 32 , wherein the antibody is monoclonal.  
     
     
         34 . The antibody of  claim 32 , wherein the antibody is murine.  
     
     
         35 . The antibody of  claim 32 , wherein the antibody is humanized.  
     
     
         36 . The antibody of  claim 32 , wherein the antibody is neutralizing.  
     
     
         37 . A method of producing an antibody to a polypeptide comprising: 
 inoculating an animal with a polypeptide selected from the group consisting of:    (a) a polypeptide consisting of 9 to 131 amino acids, wherein the polypeptide is identical to a contiguous sequence of amino acid residues in SEQ ID NO:2 from amino acid number 32 (Gln) to amino acid number 162 (Ser);    (b) a polypeptide according to  claim 1;     (c) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 41 (Gln) to amino acid number 148 (Ile);    (d) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 41 (Gln) to amino acid number 56 (Val);    (e) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 69 (Thr) to amino acid number 84 (Leu);    (f) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 92 (Asn) to amino acid number 105 (Arg);    (g) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 135 (Glu) to amino acid number 148 (Ile);    (h) a polypeptide comprising the amino acid sequence of SEQ ID NO:72;    (i) a polypeptide comprising the amino acid sequence of SEQ ID NO:73;    (j) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 32 (Gln) to amino acid number 162 (Ser);    (k) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 1 (Met) to amino acid number 162 (Ser);    (l) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 114 to amino acid number 119;    (m) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 101 to amino acid number 105;    (n) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 126 to amino acid number 131;    (o) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 113 to amino acid number 118;    (p) a polypeptide comprising the amino acid sequence of SEQ ID NO:2 from amino acid number 158 to amino acid number 162; and    wherein the polypeptide elicits an immune response in the animal to produce the antibody; and    isolating the antibody from the animal.    
     
     
         38 . An antibody produced by the method of  claim 37 , wherein the antibody binds to a zalpha11 Ligand polypeptide.

Join the waitlist — get patent alerts

Track US2007041974A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.